Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 11 de 11
Filtrer
1.
Clin Exp Dermatol ; 34(8): e889-91, 2009 Dec.
Article de Anglais | MEDLINE | ID: mdl-20055858

RÉSUMÉ

We report two Dutch infantry soldiers who acquired American cutaneous leishmaniasis (ACL) during military jungle training in Surinam. The lesions had existed for 3 and 5 months, respectively, before the soldiers presented for treatment. The lesions occurred on the head and right thigh, and were small, uncomplicated and symptomless. PCR for Leishmania revealed Leishmania naiffi in both patients. No treatment was given, and the lesions in both men healed spontaneously within 4 and 6 weeks, respectively, after presentation to our clinic. CL is one of the important 'tropical' diseases in The Netherlands, primarily due to the increasing numbers of cases in travellers and in military personnel serving overseas. ACL due to L. naiffi is thought to be a mild expression of CL with a self-limiting nature. Lesions seem to be single, mostly small, ulcerating and usually appear on the hands, arms and legs. No case of mucocutaneous leishmaniasis has yet been attributed to this parasite.


Sujet(s)
Leishmaniose cutanée/anatomopathologie , Humains , Mâle , Personnel militaire , Rémission spontanée , Suriname , Jeune adulte
2.
Ned Tijdschr Geneeskd ; 147(27): 1327-9, 2003 Jul 05.
Article de Néerlandais | MEDLINE | ID: mdl-12868163

RÉSUMÉ

A 45-year-old man from the Netherlands who travelled a lot and who had visited Cameroon, amongst other places, presented a few months after his trip with transient unilateral swellings (so-called Calabar swellings), located on his forearms, hands, fingers and feet, and which were accompanied by pruritus, pain, signs of scratching, arthralgia, general fatigue and evident eosinophilia. The differential diagnosis included strongyloidiasis, schistosomiasis, filariasis (in particular loiasis) and hypereosinophilia syndrome. Loiasis was diagnosed by means of positive IgG4 serology against Loa loa. The patient was treated with albendazole and remained free of swellings after treatment.


Sujet(s)
Albendazole/usage thérapeutique , Filaricides/usage thérapeutique , Loase/diagnostic , Animaux , Anticorps antihelminthe/sang , Cameroun , Diagnostic différentiel , Oedème/étiologie , Éosinophilie/étiologie , Humains , Immunoglobuline G/sang , Loa/immunologie , Loase/traitement médicamenteux , Mâle , Adulte d'âge moyen , Voyage , Résultat thérapeutique
3.
Neth J Med ; 59(3): 98-101, 2001 Sep.
Article de Anglais | MEDLINE | ID: mdl-11583824

RÉSUMÉ

We report on a 30-year-old Dutch marine who was stationed in Eritrea and who was repatriated because of acute paralytic small-bowel ileus. The disease course was short and without signs of infection. After diagnostic work-up, we diagnosed Yersinia enterocolitica infection. To our knowledge this is the first reported case of Yersinia enterocolitica infection causing paralytic ileus in an adult.


Sujet(s)
Maladies de l'iléon/microbiologie , Pseudo-obstruction intestinale/microbiologie , Yersinioses/complications , Yersinioses/diagnostic , Yersinia enterocolitica , Maladie aigüe , Adulte , Anti-infectieux/usage thérapeutique , Biopsie , Ciprofloxacine/usage thérapeutique , Coloscopie , Diagnostic différentiel , Humains , Mâle , Personnel militaire , Médecine navale , Pays-Bas , Tomodensitométrie , Yersinioses/traitement médicamenteux
4.
Eur J Clin Microbiol Infect Dis ; 20(6): 380-4, 2001 Jun.
Article de Anglais | MEDLINE | ID: mdl-11476436

RÉSUMÉ

The optimal duration of treatment for catheter-related Staphylococcus aureus bacteremia is not known. Short courses (< or = 2 weeks) of therapy should be viewed with caution because essential data on late complications, such as osteomyelitis and metastatic abscesses, are lacking. This study represents a retrospective analysis of the data from 49 adult patients hospitalised in the period 1994-1996 (mean age, 57 years; range, 20-90 years; 47% male) and from whom Staphylococcus aureus was cultured concomitantly from peripheral blood and catheter segments. Forty-six venous catheters, two arterial catheters, and one unknown type of catheter were used. Forty-four patients were treated with effective anti-Staphylococcus aureus antibiotics. Twenty patients had a favourable outcome, defined as no complication and no death during 1 year of follow-up, 24 patients had complications, 14 patients died due to attributable mortality, and 5 other patients died of an underlying disease without showing signs or symptoms of a complication. Patients were categorised according to the duration of treatment. There were small differences between a shorter (1-14 days) and a longer (>14 days) course of antibiotics with regard to favourable outcome (41% vs. 33%), complications (48% vs. 53%), attributable death (31% vs. 20%), and death due to underlying disease (41% vs. 33%), respectively. The rates of complications and death were high, but a definite conclusion cannot be drawn because the study was underpowered. More randomised trials are needed, but, until the results of such trials are available, the duration of therapy should not be shortened to less than 14 days.


Sujet(s)
Antibactériens/usage thérapeutique , Bactériémie/étiologie , Cathéters à demeure/effets indésirables , Infections à staphylocoques/étiologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Bactériémie/complications , Bactériémie/traitement médicamenteux , Cathétérisme veineux central/effets indésirables , Cathéters à demeure/microbiologie , Infection croisée/sang , Infection croisée/diagnostic , Infection croisée/étiologie , Contamination de matériel , Femelle , Humains , Mâle , Adulte d'âge moyen , Études rétrospectives , Infections à staphylocoques/complications , Infections à staphylocoques/traitement médicamenteux , Staphylococcus aureus/isolement et purification , Facteurs temps , Résultat thérapeutique
5.
Int J Antimicrob Agents ; 12(2): 121-7, 1999 Jul.
Article de Anglais | MEDLINE | ID: mdl-10418756

RÉSUMÉ

In this study the efficacy and cost-effectiveness of i.v. ceftriaxone 1 g once daily (CTX) was compared with standard i.v. antibiotic treatment (STD) for lower respiratory tract infections (LRTI). STD was given according to the guidelines of the American Thoracic Society and consisted of either cefuroxime 1500 mg three times daily (q8h), amoxicillin/clavulanic acid 1200 mg q8h or ceftriaxone 2 g once daily; each with or without a macrolide. After a minimum of 5 days i.v. therapy, patients could be switched to oral therapy. One hundred patients were enrolled in the study; 52 patients received CTX and 48 STD. Groups were comparable with respect to demographic and baseline characteristics. Seventy patients had a confirmed diagnosis of pneumonia. Twenty-nine patients had a severe type I exacerbation of chronic bronchitis. In one patient the diagnosis of LRTI could not be confirmed. In approximately 50% of the patients a microbiological diagnosis could be made. The most important isolated pathogens from sputum and blood were (positive blood cultures in brackets): Streptococcus pneumoniae 14 (9) and Haemophilus influenzae 16. Mean duration of i.v. therapy was 7.4 days in both groups. Average duration of hospitalisation was 15.0 days for CTX patients and 15.9 days for STD patients. Overall cure and improvement rate at the end of treatment was 47 (90%) for patients receiving ceftriaxone 1 g compared to 37 (77%) for patients receiving standard therapy. Pathogens were eradicated or presumed to be eradicated in 84% of the CTX patients and in 76% of the STD patients. Mean total costs per treatment were lower for CTX than for STD treatment: NLG 169 versus 458. These results show, that i.v. ceftriaxone 1 g once daily is as effective as standard therapy in the treatment of LRTI and that its use reduces treatment costs, in view of the multiple daily dosing regimens of most standard therapies.


Sujet(s)
Bronchite/traitement médicamenteux , Ceftriaxone/usage thérapeutique , Céphalosporines/usage thérapeutique , Pneumopathie infectieuse/traitement médicamenteux , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Association amoxicilline-clavulanate de potassium/économie , Association amoxicilline-clavulanate de potassium/usage thérapeutique , Antibactériens/économie , Antibactériens/usage thérapeutique , Bronchite/microbiologie , Ceftriaxone/économie , Céphalosporines/économie , Maladie chronique , Calendrier d'administration des médicaments , Coûts des médicaments , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Pneumopathie infectieuse/microbiologie
6.
Lancet ; 353(9148): 201-3, 1999 Jan 16.
Article de Anglais | MEDLINE | ID: mdl-9923876

RÉSUMÉ

BACKGROUND: Prophylactic drugs for Pneumocystis carinii pneumonia (PCP) are strongly recommended for HIV-1-infected patients with CD4 cell counts of less than 200 cells/microL. Because of the highly active antiretroviral therapy (HAART) currently available, we speculated that prophylaxis can be discontinued in patients with CD4 cell counts of more than 200 cells/microL. METHODS: In this prospective observational study, PCP prophylaxis (primary or secondary) was discontinued in HIV-1-infected patients whose CD4 cell count had increased above 200 cells/microL (documented twice with an interval of at least 1 month) as a result of HAART. Patients and their CD4 cell counts were monitored every 3 months. The primary endpoint of the study was the occurrence or reoccurrence of PCP. FINDINGS: 78 patients were enrolled: 62 patients were receiving prophylaxis for primary prevention of PCP and 16 patients for secondary prevention of PCP. At the time of discontinuation of prophylaxis, the mean CD4 cell count was 347 cells/microL, and HIV-1-RNA was not detectable in 61 patients. The lowest mean CD4 cell count during prophylaxis was 79 cells/microL. Patients stopped prophylaxis 9.8 (SD 6.4) months after they started HAART. The mean follow-up after discontinuation of prophylaxis was 12.7 (SD 7.6) months, and none of the patients developed PCP (97.5% one-sided CI 0-4.4%). INTERPRETATION: The preliminary results of this study indicate that PCP prophylaxis can be stopped safely in HIV-1-infected patients whose CD4 cell counts have increased above 200 cells/microL after treatment with HAART.


Sujet(s)
Infections opportunistes liées au SIDA/prévention et contrôle , Agents antiVIH/usage thérapeutique , Chimioprévention , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Pneumonie à Pneumocystis/prévention et contrôle , Numération des lymphocytes CD4 , Association de médicaments , Infections à VIH/traitement médicamenteux , Infections à VIH/immunologie , Humains , Études prospectives
7.
Antimicrob Agents Chemother ; 42(5): 1233-8, 1998 May.
Article de Anglais | MEDLINE | ID: mdl-9593156

RÉSUMÉ

In this multicenter study, the efficacy of and tolerability for meropenem were compared with those for the combination of cefuroxime-gentamicin (+/- metronidazole) for the treatment of serious bacterial infections in patients > or = 65 years of age. A total of 79 patients were randomized; thirty-nine received meropenem (1 g/8 h), and 40 received cefuroxime (1.5 g/8 h) plus gentamicin (4 mg/kg of body weight daily) for 5 to 10 days. Metronidazole (500 mg/6 h) could be added to the cefuroxime-gentamicin regimen for the treatment of intra-abdominal infections (n = 10). Seventy patients were evaluable for clinical efficacy; the primary diagnoses were as follows: pneumonia in 41 patients (20 treated with meropenem, 21 treated with cefuroxime-gentamicin), intra-abdominal infection in 10 patients (7 meropenem, 3 cefuroxime-gentamicin-metronidazole), urinary tract infection (UTI) in 11 patients (6 meropenem, 5 cefuroxime-gentamicin), sepsis syndrome in 7 patients (4 meropenem, 3 cefuroxime-gentamicin), and "other" in 1 patient (cefuroxime-gentamicin). The pathogens isolated from 18 patients with bacteremia were as follows: Staphylococcus spp. (n = 2), Streptococcus spp. (n = 2), members of the family Enterobacteriaceae (n = 11), and Bacteroides spp. (n = 3). A satisfactory clinical response at the end of therapy was achieved in 26 of 37 (70%) and 24 of 33 (73%) evaluable patients treated with meropenem and combination therapy, respectively. Clinical success was achieved in 23 of 31 (74%) and 21 of 28 (75%) evaluable patients with infections other than UTIs, respectively. A satisfactory microbiological response occurred in 15 of 22 (68%) patients in the meropenem group compared with 12 of 19 (63%) treated with combination therapy. Renal failure occurred during therapy in 2 of 39 (5%) meropenem recipients compared with 5 of 40 (13%) of those treated with combination therapy. The findings in this small study indicate that meropenem is as efficacious for and as well tolerated by elderly patients as the combination of cefuroxime-gentamicin (+/- metronidazole).


Sujet(s)
Infections bactériennes/traitement médicamenteux , Association de médicaments/usage thérapeutique , Thiénamycine/usage thérapeutique , Sujet âgé , Sujet âgé de 80 ans ou plus , Céfuroxime/administration et posologie , Céfuroxime/effets indésirables , Méthode en double aveugle , Association de médicaments/effets indésirables , Femelle , Gentamicine/administration et posologie , Gentamicine/effets indésirables , Humains , Mâle , Méropénème , Thiénamycine/effets indésirables , Résultat thérapeutique
8.
Am J Trop Med Hyg ; 57(4): 399-402, 1997 Oct.
Article de Anglais | MEDLINE | ID: mdl-9347952

RÉSUMÉ

Because of the widespread presence of chloroquine-resistant Plasmodium falciparum malaria, mefloquine is now the recommended drug of choice for long-term malaria prophylaxis in these areas. Although several studies have compared plasma and whole blood concentrations of either mefloquine or its carboxylic acid metabolite, we report the first comparison of serum and whole blood levels in 86 Dutch marines taking 250 mg of mefloquine weekly for 18 weeks while deployed in western Cambodia. All samples were taken during steady-state and at 42-48 hr after the most recent dose. The concentration of mefloquine in serum (mean = 979 ng/ml) was significantly greater than in whole blood (mean = 788 ng/ml) (P < 0.00001, by paired t-test) with an overall mean ratio of 1.28. The concentration of the metabolite in serum (mean = 3,039 ng/ml) was also significantly greater than in whole blood (mean = 1,390 ng/ml) (P < 0.00001, by paired t-test) with an overall mean ratio of 2.25. These findings are similar to previous reports of plasma-to-whole blood levels. Furthermore, we report that the within-individual ratios of the metabolite concentration to the mefloquine concentration were also found to be significantly different in serum (3.79; P < 0.00001, by paired t-test) and in whole blood (2.02; P < 0.00001, by paired t-test). Appropriate attention must be given to these differences when comparing serum and whole blood concentrations of either mefloquine or its metabolite to avoid misinterpretation of their respective levels. Also, the determination of the relative mefloquine ratios in various blood fluids, as well as the documentation of the metabolite levels and their ratios, is critical to the appropriate interpretation of both chemoprophylaxis and chemotherapy, especially in the presence of resistant strains.


Sujet(s)
Antipaludiques/sang , Paludisme à Plasmodium falciparum/prévention et contrôle , Méfloquine/sang , Antipaludiques/administration et posologie , Cambodge , Acides carboxyliques/sang , Humains , Méfloquine/administration et posologie , Personnel militaire , Pays-Bas/ethnologie
9.
Am J Trop Med Hyg ; 55(2): 230-4, 1996 Aug.
Article de Anglais | MEDLINE | ID: mdl-8780466

RÉSUMÉ

From June until October 1993, a battalion of Dutch marines was stationed in Cambodia for a United Nations deployment. In 73 volunteers who used mefloquine as malaria chemoprophylaxis, possible mefloquine-related adverse events were monitored with special emphasis on QT prolongation. All participants started mefloquine chemoprophylaxis with a loading dose (250 mg a day for three days) one week before departure, followed by a weekly dose (250 mg) for approximately 25 weeks. One month before (t - 1) and one (t + 1) and three (t + 3) months after mefloquine prophylaxis was started, an at rest electrocardiogram was made. Frequency, PR-, and QT-intervals were measured; blood samples for liver transaminases, total white blood cell count, and mefloquine concentration were obtained after one and three months. Adverse events such as dizziness, headache, coordination problems, and nausea were spontaneously reported in one (1.4%) and three (4.1%) persons at t + 1 and t + 3, respectively, while specific questioning revealed adverse events in nine (12.3%) and five (6.9%) persons, respectively, at the same time point. Three months after starting chemoprophylaxis, the heart rate at rest and total white blood cell count were lower (P < 0.05), while the QTc-interval was longer and levels of liver transaminases increased (P < 0.05), although both were still within the normal range. There was no extreme prolongation of the QTc-interval or increased levels of liver transaminases that resulted in a need to stop the chemoprophylaxis. No accumulation of mefloquine in the serum occurred, and no relationship was observed between the incidence of adverse events and serum mefloquine concentrations. The incidence of self reported mefloquine-related adverse events was low. In conclusion, mefloquine chemoprophylaxis was safe and well-tolerated in this group.


Sujet(s)
Antipaludiques/effets indésirables , Paludisme à Plasmodium falciparum/prévention et contrôle , Méfloquine/effets indésirables , Personnel militaire , Adulte , Antipaludiques/sang , Antipaludiques/usage thérapeutique , Cambodge , Diarrhée/induit chimiquement , Sensation vertigineuse/induit chimiquement , Électrocardiographie/effets des médicaments et des substances chimiques , Coeur/effets des médicaments et des substances chimiques , Humains , Numération des leucocytes/effets des médicaments et des substances chimiques , Mâle , Méfloquine/sang , Méfloquine/usage thérapeutique , Adulte d'âge moyen , Pays-Bas , Performance psychomotrice/effets des médicaments et des substances chimiques
11.
Neth J Med ; 44(4): 122-30, 1994 Apr.
Article de Anglais | MEDLINE | ID: mdl-8196822

RÉSUMÉ

According to a standard protocol 115 patients (96 type 2 DM, 19 type 1 DM) were treated with a 3 litre glucose 5%/day infusion, KCl and insulin, with the aim of obtaining near-normoglycaemia perioperatively. Blood glucoses of 6.7-10.0 mmol/l were scored as ideal, 3.5-15.0 mmol/l as acceptable, and the remaining values as unacceptable. In 32 patients (28%) the protocol was followed in all aspects, whereas in 45 patients (39%) the protocol was followed in therapeutic aspects (total n = 77.67%, Group 1). In the remaining 38 patients (33%) protocol violations occurred (Group 2). In 48 patients (62%) of Group 1 ideal or acceptable control was obtained perioperatively versus 11 patients (29%) of Group 2 (p < 0.05). In patients with good preoperative long-term regulation (HbA1 < or = 8.0%; n = 81) ideal or acceptable perioperative control was achieved in 58% (n = 47) versus 13% (n = 4) of those (n = 31) with preoperative HbA1 > 8.0% (p < 0.05). Stepwise multiple logistic regression analysis showed that preoperative long-term regulation (HbA1; p < 0.001) and adherence to the protocol (p = 0.022) were the only independent variables with prognostic significance for perioperative blood glucose control. In 17 patients (15%) minor electrolyte disturbances occurred. No patient had frank ketosis. Duration of disease, presence of complications, type of anaesthesia and operation did not affect perioperative diabetes control.(ABSTRACT TRUNCATED AT 250 WORDS)


Sujet(s)
Diabète , Procédures de chirurgie opératoire , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Glycémie/analyse , Diabète/sang , Diabète/thérapie , Femelle , Humains , Mâle , Adulte d'âge moyen , Soins postopératoires , Soins préopératoires
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE